Skip to contentH
Haemonetics Corp
H
HAEHaemonetics Corp Q1 2027 · 10-Q
Revenue$339.38M$339.38M+5.6% vs Q1 2026 Net Income$33.01M$33.01M−3.0% vs Q1 2026 EPS Diluted$0.72$0.72+2.9% vs Q1 2026 Gross Profit$202,803,000+5.5% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Haemonetics Corp · CIK 313143 · Engraved from SEC EDGAR
Operating Cash Flow$52,323,000+200.8% Free Cash Flowderived$44,417,000+225.6% Margins · derivedGross margin59.8%−0.1 pt vs Q1 2026
Operating margin16.9%+0.2 pt vs Q1 2026
Net margin9.7%−0.9 pt vs Q1 2026
ended Jun 27, 2026 · filed Aug 6, 2026 · 40 d after period end